Literature DB >> 19732061

Disruption of nNOS-PSD95 protein-protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents.

S K Florio1, C Loh, S M Huang, A E Iwamaye, K F Kitto, K W Fowler, J A Treiberg, J S Hayflick, J M Walker, C A Fairbanks, Y Lai.   

Abstract

BACKGROUND AND
PURPOSE: Post-synaptic density protein 95 (PSD95) contains three PSD95/Dosophilia disc large/ZO-1 homology domains and links neuronal nitric oxide synthase (nNOS) with the N-methyl-D-aspartic acid (NMDA) receptor. This report assesses the effects of disruption of the protein-protein interaction between nNOS and PSD95 on pain sensitivity in rodent models of hyperalgesia and neuropathic pain. EXPERIMENTAL APPROACH: We generated two molecules that interfered with the nNOS-PSD95 interaction: IC87201, a small molecule inhibitor; and tat-nNOS (residues 1-299), a cell permeable fusion protein containing the PSD95 binding domain of nNOS. We then characterized these inhibitors using in vitro and in vivo models of acute hyperalgesia and chronic allodynia, both of which are thought to require nNOS activation. KEY
RESULTS: IC87201 and tat-nNOS (1-299) inhibited the in vitro binding of nNOS with PSD95, without inhibiting nNOS catalytic activity. Both inhibitors also blocked NMDA-induced 3',5'-cyclic guanosine monophosphate (cGMP) production in primary hippocampal cultures. Intrathecal administration of either inhibitor potently reversed NMDA-induced thermal hyperalgesia in mice. At anti-hyperalgesic doses, there was no effect on acute pain thresholds or motor coordination. Intrathecal administration of IC87201 and tat-nNOS also reversed mechanical allodynia induced by chronic constriction of the sciatic nerve. CONCLUSIONS AND IMPLICATIONS: nNOS-PSD95 interaction is important in maintaining hypersensitivity in acute and chronic pain. Disruption of the nNOS-PSD95 interaction provides a novel approach to obtain selective anti-hyperalgesic compounds.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19732061      PMCID: PMC2757689          DOI: 10.1111/j.1476-5381.2009.00300.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  48 in total

1.  Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions.

Authors:  Michelle Aarts; Yitao Liu; Lidong Liu; Shintaro Besshoh; Mark Arundine; James W Gurd; Yu-Tian Wang; Michael W Salter; Michael Tymianski
Journal:  Science       Date:  2002-10-25       Impact factor: 47.728

Review 2.  Novel treatment of excitotoxicity: targeted disruption of intracellular signalling from glutamate receptors.

Authors:  Michelle M Aarts; Michael Tymianski
Journal:  Biochem Pharmacol       Date:  2003-09-15       Impact factor: 5.858

Review 3.  Spinal delivery of analgesics in experimental models of pain and analgesia.

Authors:  Carolyn A Fairbanks
Journal:  Adv Drug Deliv Rev       Date:  2003-08-28       Impact factor: 15.470

Review 4.  Cell signaling and the genesis of neuropathic pain.

Authors:  Ru-Rong Ji; Gary Strichartz
Journal:  Sci STKE       Date:  2004-09-21

5.  Nociceptive action of excitatory amino acids in the mouse: effects of spinally administered opioids, phencyclidine and sigma agonists.

Authors:  L M Aanonsen; G L Wilcox
Journal:  J Pharmacol Exp Ther       Date:  1987-10       Impact factor: 4.030

6.  Knockdown of PSD-95/SAP90 delays the development of neuropathic pain in rats.

Authors:  F Tao; Y X Tao; J A Gonzalez; M Fang; P Mao; R A Johns
Journal:  Neuroreport       Date:  2001-10-29       Impact factor: 1.837

7.  Neuropathic sensitization of behavioral reflexes and spinal NMDA receptor/CaM kinase II interactions are disrupted in PSD-95 mutant mice.

Authors:  Emer M Garry; Andrew Moss; Ada Delaney; Francis O'Neill; James Blakemore; Julian Bowen; Holger Husi; Rory Mitchell; Seth G N Grant; Susan M Fleetwood-Walker
Journal:  Curr Biol       Date:  2003-02-18       Impact factor: 10.834

8.  Chronic catheterization of the spinal subarachnoid space.

Authors:  T L Yaksh; T A Rudy
Journal:  Physiol Behav       Date:  1976-12

Review 9.  Molecular mechanisms underlying specificity of excitotoxic signaling in neurons.

Authors:  Michelle M Aarts; Michael Tymianski
Journal:  Curr Mol Med       Date:  2004-03       Impact factor: 2.222

10.  Intrathecal morphine in mice: a new technique.

Authors:  J L Hylden; G L Wilcox
Journal:  Eur J Pharmacol       Date:  1980-10-17       Impact factor: 4.432

View more
  37 in total

1.  Disrupting 5-HT(2A) receptor/PDZ protein interactions reduces hyperalgesia and enhances SSRI efficacy in neuropathic pain.

Authors:  Xavier Pichon; Anne S Wattiez; Carine Becamel; Ingrid Ehrlich; Joel Bockaert; Alain Eschalier; Philippe Marin; Christine Courteix
Journal:  Mol Ther       Date:  2010-06-08       Impact factor: 11.454

Review 2.  Glutamate receptor phosphorylation and trafficking in pain plasticity in spinal cord dorsal horn.

Authors:  Xue Jun Liu; Michael W Salter
Journal:  Eur J Neurosci       Date:  2010-07-11       Impact factor: 3.386

3.  Fashioning drugs for stroke.

Authors:  Ted Weita Lai; Yu Tian Wang
Journal:  Nat Med       Date:  2010-12       Impact factor: 53.440

4.  Disrupting specific PDZ domain-mediated interactions for therapeutic benefit.

Authors:  Miles D Houslay
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

Review 5.  Ionotropic glutamate receptors in spinal nociceptive processing.

Authors:  Max Larsson
Journal:  Mol Neurobiol       Date:  2009-10-31       Impact factor: 5.590

Review 6.  Modulation of nociceptive ion channels and receptors via protein-protein interactions: implications for pain relief.

Authors:  Tom Rouwette; Luca Avenali; Julia Sondermann; Pratibha Narayanan; David Gomez-Varela; Manuela Schmidt
Journal:  Channels (Austin)       Date:  2015-06-03       Impact factor: 2.581

Review 7.  Emerging Themes in PDZ Domain Signaling: Structure, Function, and Inhibition.

Authors:  Xu Liu; Ernesto J Fuentes
Journal:  Int Rev Cell Mol Biol       Date:  2018-06-28       Impact factor: 6.813

8.  Disrupting interaction of PSD-95 with nNOS attenuates hemorrhage-induced thalamic pain.

Authors:  Weihua Cai; Shaogen Wu; Zhiqiang Pan; Jifang Xiao; Fei Li; Jing Cao; Weidong Zang; Yuan-Xiang Tao
Journal:  Neuropharmacology       Date:  2018-09-05       Impact factor: 5.250

9.  Identification of a small-molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD.

Authors:  Thor S Thorsen; Kenneth L Madsen; Nelson Rebola; Mette Rathje; Victor Anggono; Anders Bach; Irina S Moreira; Nicolai Stuhr-Hansen; Tino Dyhring; Dan Peters; Thijs Beuming; Richard Huganir; Harel Weinstein; Christophe Mulle; Kristian Strømgaard; Lars Christian B Rønn; Ulrik Gether
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

10.  Small-molecule inhibitors at the PSD-95/nNOS interface have antidepressant-like properties in mice.

Authors:  Marika V Doucet; Hester Levine; Kumlesh K Dev; Andrew Harkin
Journal:  Neuropsychopharmacology       Date:  2013-02-27       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.